More Reuters
View Older Stories View Newer Stories-
Navigation specialist TomTom's 2024 revenue drops on automotive market concerns
-
Navigation specialist TomTom's 2024 revenue drops on automotive market concerns
-
Navigation specialist TomTom's 2024 revenue drops on automotive market concerns
-
Navigation specialist TomTom's 2024 revenue drops on automotive market concerns
-
Navigation specialist TomTom's 2024 revenue drops on automotive market concerns
-
TomTom sees lower 2025 earnings on automotive market slowdown, shares drop
-
Amundi posts in-line Q4 inflows on risk-averse products
-
Amundi posts in-line Q4 inflows on risk-averse products
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas beats Q4 forecast but trims profit target for year ahead
-
BNP Paribas' investment bank shines in boost for shares
-
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
-
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
-
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
-
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
-
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
-
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
-
France in focus as Europe's electricity import needs swell: Maguire
-
France in focus as Europe's electricity import needs swell: Maguire
-
At least five killed in prison riot in Tajikistan, sources say
-
Five Islamic State prisoners killed trying to escape from Tajik jail, source says
-
Software firm Dassault Systemes sees higher sales, earnings in 2025
-
In shock announcement, Trump says U.S. wants to take over Gaza Strip
-
Citi sticks to hybrid working, bucks return-to-office trend, FT reports
-
China announces measures against Google, other US firms, as trade tensions escalate
-
US Vice President Vance will attend AI summit in Paris, says French diplomatic source
-
UBS CEO takes aim again at Swiss capital rules, spooking shares
-
China puts PVH Corp, Illumina on its unreliable entity list
-
Instant View: China announces tit-for-tat tariffs as US levies come into effect
-
Analysis-Europe's AI bulls pin hopes on 'Jevons Paradox' after DeepSeek rout
-
Morning Bid: China tariffs on, but everything's negotiable
-
China's finance ministry announces tariffs to counter Trump trade moves
-
Egypt's non-oil private sector posts growth in January, PMI shows
-
Trump in no hurry to talk to Xi amid new tariff war
-
Saudi Arabia's non-oil private sector grows at decade-high pace in Jan, PMI shows
-
Philippines, U.S. hold joint air patrol over South China Sea, angering China
-
Israel asks public to put solar panels on roofs to produce electricity
-
KKR sweetens offer for Fuji Soft as bidding war with Bain goes another round
